Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 854

recruiting
3 987
countries
28
conditions
2 109

10 381 trials match your criteria

Small intestine adenocarcinoma

Not recruiting

Study on the Effectiveness of Chemotherapy with Fluorouracil, Capecitabine, and Oxaliplatin for Patients with Small Bowel Adenocarcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine

Neuroendocrine carcinoma metastatic

Not recruiting

Study of AdVince (Modified Adenovirus) Treatment Through Hepatic Artery Injection in Patients with Advanced Neuroendocrine Neoplasms

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Human Adenovirus C Serotype 5 With E1 Gene Controlled By Chromogranin A Promoter And Hexon Modified With Protein Transduction Domain Motif

Acute myeloid leukaemia+1

Not recruiting

Study Comparing CPX-351 and Conventional Drug Combination for Patients with High-Risk Myelodysplastic Syndromes and Oligoblastic Acute Myeloid Leukemia Before Stem Cell Transplant

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine

Mantle cell lymphoma

Not recruiting

Study on Obinutuzumab, Venetoclax, and Ibrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib

Diabetic neuropathy+1

Not recruiting

Study on the Effectiveness of ODM-111 and Paracetamol for Chronic Pain in Patients with Diabetic Peripheral Neuropathy

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:ODM-111

B-cell lymphoma

Not recruiting

Study of Loncastuximab Tesirine for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma or High-Grade B-Cell Lymphoma After CAR T-Cell Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Loncastuximab Tesirine

Renal transplant

Not recruiting

Study on Tacrolimus for Children After Kidney Transplant: Comparing Immediate and Prolonged-Release Forms

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Tacrolimus

Breast cancer+2

Not recruiting

Study of Durvalumab, Olaparib, and Fulvestrant for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer with Specific Genetic Alterations

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab

Thermal burn

Not recruiting

Study on the Safety and Effectiveness of EHSG-KF for Treating Deep Dermal and Full Thickness Burns in Children

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Bilayer Engineered Collagen Hydrogel-Based Skin Graft Composed Of Autologous Keratinocytes And Fibroblasts

Acute respiratory distress syndrome+3

Not recruiting

Study on Imlifidase for Patients with Severe ANCA-Associated Vasculitis and Lung Bleeding

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Imlifidase

Chondrosarcoma

Not recruiting

Study of INBRX-109 (ozekibart) compared to placebo in adults with unresectable or metastatic chondrosarcoma - a rare bone cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Acetylcysteine

Cystic fibrosis

Not recruiting

Study on Long-term Safety and Efficacy of Elexacaftor, Tezacaftor, and Ivacaftor for Cystic Fibrosis in Patients Aged 12 Months and Older

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years
  • Substances:Elexacaftor

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.